<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880279</url>
  </required_header>
  <id_info>
    <org_study_id>TAC01-CD19-01</org_study_id>
    <nct_id>NCT03880279</nct_id>
  </id_info>
  <brief_title>Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma</brief_title>
  <acronym>TACTIC-19</acronym>
  <official_title>A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triumvira Immunologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Triumvira Immunologics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II study to evaluate TAC01-CD19 in subjects with relapsed or refractory B-cell
      lymphomas. TAC technology is a novel way to genetically modify T cells and to redirect these
      T cells to target cancer antigens by co-opting the natural T cell receptor. The dose finding
      portion of this study will evaluate the safety and tolerability of increasing dose levels of
      TAC01-CD19 to identify a Maximal Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).
      The dose expansion portion of the study will further evaluate the safety, efficacy and
      pharmacokinetics of TAC01-CD19 at the RP2D.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>First 28 days after dosing</time_frame>
    <description>Measurement of occurrence of study-defined DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Informed consent through 2 years after dosing</time_frame>
    <description>Type, frequency, and severity of adverse events (AEs) and laboratory abnormalities</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>TAC01-CD19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TAC01-CD19</intervention_name>
    <description>Dose-escalating cohorts plus expansion groups</description>
    <arm_group_label>TAC01-CD19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed CD19+ Large B-Cell Lymphoma including Diffuse Large B-cell
             Lymphoma (DLBCL) not otherwise specified (including de novo and transformed lymphoma),
             Primary Mediastinal Large B-cell Lymphoma, High-Grade B-cell Lymphoma with MYC and
             BCL2 and/or BCL6 rearrangement per WHO 2016 classification.

          -  Relapsed or refractory disease after greater than 2 lines of therapy including
             anthracycline and anti-CD20 therapy and either having failed autologous stem cell
             transplant (ASCT) or being ineligible for ASCT.

          -  ECOG 0-1.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Prior treatment with any of the following: allogeneic bone marrow transplantation,
             gene therapy, adoptive cell transfer of any kind, including CAR T cells.

          -  Active central nervous system (CNS) lymphoma involvement.

          -  History or presence of clinically relevant CNS pathology.

          -  Active inflammatory neurological disorders, autoimmune disease, or infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

